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Research Article
The Hippo/YAP pathway interacts with EGFR
signaling and HPV oncoproteins to regulate cervical
cancer progression
Chunbo He1,2, Dagan Mao1,3, Guohua Hua1,2, Xiangmin Lv1, Xingcheng Chen4, Peter C Angeletti5,
Jixin Dong4, Steven W Remmenga1,4, Kerry J Rodabaugh1, Jin Zhou1,6, Paul F Lambert7, Peixin Yang8,
John S Davis1,4,9 & Cheng Wang1,4,*
Abstract
The Hippo signaling pathway controls organ size and tumorigene-
sis through a kinase cascade that inactivates Yes-associated
protein (YAP). Here, we show that YAP plays a central role in
controlling the progression of cervical cancer. Our results suggest
that YAP expression is associated with a poor prognosis for cervical
cancer. TGF-a and amphiregulin (AREG), via EGFR, inhibit the Hippo
signaling pathway and activate YAP to induce cervical cancer cell
proliferation and migration. Activated YAP allows for up-regulation
of TGF-a, AREG, and EGFR, forming a positive signaling loop to
drive cervical cancer cell proliferation. HPV E6 protein, a major
etiological molecule of cervical cancer, maintains high YAP protein
levels in cervical cancer cells by preventing proteasome-dependent
YAP degradation to drive cervical cancer cell proliferation. Results
from human cervical cancer genomic databases and an accepted
transgenic mouse model strongly support the clinical relevance of
the discovered feed-forward signaling loop. Our study indicates
that combined targeting of the Hippo and the ERBB signaling path-
ways represents a novel therapeutic strategy for prevention and
treatment of cervical cancer.
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Introduction
Cervical cancer is the second most commonly diagnosed cancer and
the fourth leading cause of cancer death in women worldwide
(Jemal et al, 2011). The estimate from the International Agency for
Research on Cancer (IARC) predicted that 528,000 women would be
diagnosed with cervical cancer and 266,000 deaths would result
from this disease in 2012 (Ferlay et al, 2013). Cervical cancer affects
women when they are still young and has devastating effects with a
very high human, social, and economic cost. Human papillomavirus
(HPV) infection is detected in 99.7% of cervical cancer patients and
is believed to be the major risk factor for cervical cancer (Jemal
et al, 2011; Ferlay et al, 2013). However, epidemiological studies
have shown that although the estimated lifetime risk of HPV infec-
tion is more than 75% (Koutsky, 1997), the lifetime risk of develop-
ing cervical cancer is only around 0.7% (Siegel et al, 2014). It is
clear that HPV alone is insufficient for malignant transformation
and uncontrolled growth of cervical epithelium (Mahdavi & Monk,
2005; Chan & Berek, 2007). The exact molecular mechanisms under-
lying cervical cancer initiation and progression are largely
unknown.
The Hippo signaling pathway, originally discovered in Droso-
phila, is an evolutionarily conserved pathway that controls organ
size by regulating cell proliferation in a diverse number of species.
The core Hippo pathway, consisting of a kinase cascade and associ-
ated co-activators and scaffold proteins, has been well established in
both Drosophila and mammals (Pan, 2010; Mo et al, 2014). In the
mammalian Hippo pathway, macrophage stimulating 1/2 kinase
(MST1/2, called Hippo in Drosophila), in complex with Salvador
homolog 1 (Sav1), phosphorylates the large tumor suppressor kinase
1/2 (LATS1/2) and a regulatory protein, Mps one binder kinase
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activator-like 1A (MOB1). Phosphorylated LATS1/2 and MOB1 form
an interaction complex that leads to activation of LATS1/2. Activated
LATS1/2, in turn, phosphorylates the growth-promoting transcrip-
tional co-activator Yes-associated protein (YAP1, or more commonly
YAP). Phosphorylation of YAP leads to its cytoplasmic retention
and/or degradation, depending on the sites of phosphorylation
(Dong et al, 2007; Zhao et al, 2007; Pan, 2010; Mo et al, 2014).
Conversely, loss of the Hippo signaling can lead to organ overgrowth
and induce tumors in model organisms (Dong et al, 2007; Lee et al,
2010). Dysregulation of the Hippo pathway occurs in a broad range
of human carcinomas, including lung, colorectal, breast, ovarian,
pancreatic, gastric, and liver cancer (Hall et al, 2010; Lee et al, 2010;
Wang et al, 2010, 2012b; Kang et al, 2011; Zhang et al, 2011;
Avruch et al, 2012; Hergovich, 2012; He et al, 2015). However,
whether the Hippo pathway plays a role in the progression of cervi-
cal cancer development is currently unknown.
Yes-associated protein is the major downstream effector of the
Hippo pathway (Pan, 2010). Recent studies suggest that expression
and function of YAP in cancer are cell type and/or cellular context
dependent. Several studies define YAP as an oncogene. For exam-
ple, the amplification of the YAP gene locus at 11q22 is found in
several types of cancers (Snijders et al, 2005; Overholtzer et al,
2006; Zender et al, 2006; Fernandez et al, 2009; Kang et al, 2011;
Muramatsu et al, 2011). Overexpression and nuclear localization of
the YAP protein has been noted in colon, liver, lung, ovarian, and
prostate cancers (Snijders et al, 2005; Zhao et al, 2007; Steinhardt
et al, 2008; Zhang et al, 2011; Yu & Guan, 2013; He et al, 2015).
Overexpression of YAP induced oncogenic transformation of an
immortalized breast epithelial cell line, MCF10A (Overholtzer et al,
2006), and significantly stimulated granulosa cell tumor cell prolifer-
ation (Fu et al, 2014). On the other hand, YAP was reported to be a
tumor suppressor in certain cell types. YAP has been shown to
enhance p73-dependent cell death during cisplatin-induced DNA
damage (Strano et al, 2005). In a subset of breast cancers, YAP
protein expression was significantly decreased due to loss of
heterozygosity. Additionally, shRNA knockdown of YAP increased
anchorage-independent growth, migration, and invasiveness of
breast cancer cells and enhanced tumor growth in nude mice (Yuan
et al, 2008). However, the precise mechanism for the expression
and function of YAP in cervical cancer cell remains undefined.
In the present study, we sought to determine the expression of
YAP in human cervical cancer tissues, and to examine the role of
the Hippo pathway in the progression of cervical cancer. We found
that YAP is overexpressed in cervical cancer tissue. We also found
that the Hippo signaling pathway, through interaction with the
EGFR signaling pathway, regulates progression of cervical cancer
via an autocrine loop involving EGF-like ligands, EGFR, and the
Hippo pathway. Importantly, we discovered that the HPV E6 protein
stabilizes the YAP protein to maintain its action on the progression
of cervical cancer.
Results
YAP expression during cervical cancer progression
Compared with normal control tissues, both the positivity and inten-
sity of the YAP immunosignal, which indicate YAP-positive cells and
YAP protein levels, respectively, were significantly higher in the cervi-
cal cancer tissues (Fig 1A and B, Tables 1 and 2). We also found that
YAP expression and localization were associated with tumor stage.
Compared with tumor tissue from patients with early-stage disease
(Fig 1D, E and G), tissue from patients with advanced-stage cervical
cancer had significantly higher levels of YAP protein, which was
localized mainly to the nucleus of tumor cells (Fig 1F and H).
The relationships between YAP protein levels and clinical
histopathological parameters were also analyzed in this study. As
described in Table 2, YAP positivity was greater in cervical cancer
tissues compared to normal tissues, but the number of YAP-positive
cells in cervical cancer did not vary with age, grade, stage, primary
tumor, and regional lymph node status. Notably, the intensity of
YAP immunosignal (expression levels) was significantly correlated
with the FIGO stage, primary tumor, and regional lymph node
status, but not the tumor grade (Table 2).
Western blot analyses showed that YAP was differentially
expressed in normal and cancerous cervical cell lines (Appendix
Fig S1A). Consistent with IHC results, YAP was highly expressed in
cervical cancer cell lines (ME180, HT3, and HeLa), while in Ect1
cells, an immortalized epithelial cell line derived from the ectocervi-
cal epithelium, YAP protein was expressed at low levels and was
highly phosphorylated (Appendix Fig S1A).
To confirm that YAP plays a role in human cervical cancer
progression, we analyzed YAP gene alteration using data extracted
from The Cancer Genomic Atlas (TCGA) database and the cBioPortal
online analyzing tool (the cBioPortal for Cancer Genomics) (Cerami
et al, 2012; Gao et al, 2013). The cross-cancer YAP alteration analy-
sis shows that YAP is frequently altered in different types of cancers
(Fig 1I). Interestingly, among 36 examined cancer types or subtypes
Figure 1. YAP expression in normal cervical tissues and cervical cancers.
A Representative images show expression of YAP in normal cervical tissues, early-stage cervical cancer (stage I & II), and advanced-stage cervical cancer (stage III
& IV). Note the significant increase in YAP immunosignals (brown staining) in the advanced-stage tumors. Tissue core size: 1.5 mm.
B Positivity (percentage of positively stained cells relative to the total number of cells in the tissue section) of YAP immunosignals in the normal and cancerous
tissues. Data were analyzed with unpaired t-test in GraphPad Prism 5 with Welch’s correction. Bars represent means  SEM (n = 10 for normal tissues; n = 69 for
tumor tissues; ***P < 0.0001).
C A representative image showing the expression of YAP (brown staining) in normal cervical tissue. Scale bar = 20 lm.
D–F Representative images showing the expression of YAP in (D) early-stage cervical cancer tissue (stage Ib, T1N0M0); (E) medium-stage cervical cancer tissue (stage
IIb, T2N0M0); and (F) advanced-stage cervical cancer tissue (stage IIIb, T3N1M0). Scale bar = 20 lm.
G, H High-resolution images showing the cellular location of YAP in (G) early-stage cervical cancer tissue and (H) advanced-stage cervical cancer tissue. Scale
bar = 20 lm.
I Multidimensional cancer genomics data analysis results showing cross-cancer YAP gene alteration. The histogram showed the frequencies of YAP gene mutation,
deletion, and amplification across cancers. Data were extracted from TCGA database and analyzed using cBioPortal online analyzing tools. The results indicate that
the highest alteration frequency of YAP gene occurs in cervical cancer.
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(from a total of 90 studies), the cervical cancer has the highest
frequency of YAP gene amplification (Fig 1I). Intriguingly, Analysis
of the cervical cancer patient sample from the TCGA datasets indi-
cated that upstream genes involved in the Hippo tumor-suppressing
pathway are frequently deleted and mutated, while the effectors,
YAP and WWTR1 (TAZ) genes, are frequently amplified in 191
cervical cancer cases (Fig EV1A). Further analysis using 135 cervical
cancer genome sequencing data from TCGA datasets indicates that
YAP gene is altered in 17% examined cases (Fig EV1). TEADs are
the major mediators of YAP transcriptional activities. In the exam-
ined cervical cancer patient samples, 42% cases have alterations in
at least one of the genes in YAP-TEAD complex (Fig EV1B). More-
over, network analysis showed that almost all genes that interacted
with YAP, including other YAP-associated transcriptional factors
such as ERBB4, Runx1, and Runx2, are up-regulated in various
degrees in examined cervical cancer cases (Appendix Fig S2).
YAP promotes proliferation and migration of cervical cancer cells
in vitro
Since YAP is overexpressed in cervical cancer, we used ME180
(HPV positive) and HT3 (HPV negative) cervical cancer cell lines
to clarify the role of YAP in cervical cancer cell proliferation. We
established six cell lines with differential YAP protein levels and
activities: ME180-YAPS127A and HT3-YAPS127A cell lines express-
ing constitutively activated YAP; ME180-YAP and HT3-YAP
overexpressing wild-type YAP; and ME180-MXIV and HT3-MXIV
cells transfected with control vectors (MXIV). As expected, YAP was
overexpressed in ME180-YAP, HT3-YAP, ME180-YAPS127A, and
HT3-YAPS127A cells (Fig 2A and C, Appendix Fig S3A and B). An
increase in phosphorylated YAP was observed in the ME180-YAP
and HT3-YAP cells, but not in ME180-YAPS127A and HT3-YAPS127A
cells, consistent with the mutation of serine 127 to alanine (Fig 2A
and C, Appendix Fig S3A and B), which results in constitutive YAP
activity (Pan, 2010). We observed that in the presence of complete
medium (10% serum for HT3, 2.5% serum for ME180), the growth
rate of the ME180 and HT3 cell lines was similar prior to reaching
confluence. After reaching confluence (> 4 days after cell plating),
cells in the control groups almost stopped proliferating. However,
cells overexpressing YAP or YAPS127A continued to proliferate
(Fig 2B and D), with the highest growth rates observed in ME180-
YAPS127A and HT3-YAPS127A cells. Interestingly, when examined
under serum-reduced conditions (1% FBS), the growth rate of the
ME180-YAPS127A cells was significantly higher than that of the
ME180-YAP cells, while growth rate of the ME180-YAP cells was
significantly higher than that of ME180-MXIV cells, even before the
cell cultures reach confluence (Appendix Fig S3C). We then
analyzed cell cycle progression in these cell lines after they reached
confluence. The results showed that overexpression or constitutive
activation of YAP increased the percentage of cells in S and G2/M
phases, and reduced the proportion of cells in G1 phase in both
ME180 and HT3 cervical cancer cells (Appendix Fig S4).
The cervical epithelial cell line Ect1/E6E7 was immortalized with
HPV16 E6/E7 and is considered to be an immortalized non-tumori-
genic ectocervical epithelial cell line (Fichorova et al, 1997;
Fichorova & Anderson, 1999). We used this cell line to determine
whether YAP was able to stimulate the proliferation of immortalized
cervical epithelial cells. We established three cell lines based on
Ect1/E6E7 cells: Ect1-MXIV (Ect1/E6E7 cells transfected with an
empty control vector), Ect1-YAP (Ect1/E6E7 cells overexpressing
wild-type YAP), and Ect1-YAPS127A cells (Ect1/E6E7 cells overex-
pressing constitutively active YAP). Western blot detection of phos-
phorylated and total YAP levels in these cells showed that YAP was
successfully overexpressed in Ect1-YAP and Ect1-YAPS127A cells
(Fig 2E). Morphologically, Ect1-YAPS127A cells formed many cell
plaques, which may be attributed to multilayered cell growth
(Appendix Fig S5). As expected, the cell growth curve showed that
Ect1-YAPS127A cells proliferated faster and Ect1-MXIV cells prolifer-
ated slower than Ect1-YAP cells (Fig 2F).
To confirm that YAP plays a role in regulating the proliferation of
cervical cancer cells, we used YAP siRNA to knock down YAP
protein in ME180 and HT3 cells. Non-targeting control siRNA
(siCtrl) was used as a control. Western blot analysis demonstrated
that YAP siRNA successfully reduced YAP protein level in ME180
and HT3 cells (Fig 2G, Appendix Fig S6A). Knockdown of YAP
protein did not affect HT3 cell proliferation until day 4, when the
cells achieved a higher density (≥ 90%). After day 4, control HT3
cells treated with non-targeting control siRNA (siCtrl) continued to
proliferate, although the growth rate was lower than in low-density
cells. However, HT3 cells treated with YAP siRNA stopped growing
(Fig 2H). Similarly, after day 4, the growth rate of control ME180
Table 1. Positivitya of YAP immunosignal in normal cervical tissues
and cervical tumors.
Signal Intensity Tumor (n = 69) Normal (n = 10)
Negative 2.9% (2/69) 60% (6/10)
Weak 5.8% (4/69) 40% (4/10)
Moderate 13.0% (9/69) 0
Strong 78.3% (54/69) 0
aPositivity: the ratio of immunosignal-positive cell number to the total cell
number. Signal intensity was classified as follows: negative, positivity < 1%;
weak, 1% < positivity < 10%; moderate, 10% < positivity < 20%; and strong,
positivity > 20%.
Table 2. Correlation between YAP expression and the
clinicopathologic determinants in cervical cancer.
Feature IP (P) Positivity (P)
Tumor vs. Normal 0.021 < 0.0001
Grade 0.512 0.645
Stage < 0.0001 0.444
T 0.0008 0.647
N 0.002 0.312
Age 0.080 0.362
IP = total intensity of positive signal.
Positivity: the ratio of immunosignal-positive cell number to the total cell
number.
T: primary tumor: T1—tumor invades submucosa; T2—tumor invades
muscularis propria; T3—tumor invades through muscularis propria into
subserosa or into non-peritonealized pericolic or perirectal tissues;
T4—tumor directly invades other organs or structures and/or perforate
visceral peritoneum.
N: regional lymph nodes: N0—no regional lymph node metastasis;
N1—metastasis in 1–3 regional lymph nodes; N2—metastasis in 4 or more
regional lymph nodes.
M: distant metastasis: M0—no distant metastasis; M1—distant metastasis.
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cells (siCtrl) was significantly higher than in siYAP treatment
ME180 cells (Appendix Fig S6B). This is consistent with our finding
that YAP protein level and activity in ME180 cervical cancer cells
were associated with cell density. YAP protein in ME180 cells
allowed to proliferate to high density in culture was highly phospho-
rylated (Appendix Fig S1B). Phosphorylation of YAP at serine 127
leads to sequestration of YAP in the cytoplasm, leading to its inacti-
vation (Zender et al, 2006; Fernandez et al, 2009).
Wound-healing assays showed that, compared to the controls,
overexpression or constitutive activation of YAP leads to significant
increases in wound closure (P < 0.001), indicating that YAP also
plays an important role in the regulation of cervical cancer cell
migration (Appendix Fig S7).
YAP is able to transform cervical epithelial cells and enhances
anchorage-independent cervical cancer cell growth
As mentioned above, Ect1/E6E7 (Ect1) cell was immortalized with
HPV16 E6/E7 and is considered to be an immortalized ectocervical
epithelial cell line (Fichorova et al, 1997; Fichorova & Anderson,
1999). Therefore, the three cell lines derived from this cell line are
proper cellular models to determine whether YAP can transform
cervical epithelial cells using a soft agar colony formation assay.
When grown on soft agar, Ect1-MXIV cells only formed a few very
small, slow-growing colonies after 9 days. However, Ect1-YAP cells
and Ect1-YAPS127A cells formed many large colonies on soft agar
(Fig 3A and B). The formation of colonies by the Ect1-MXIV may be
attributed to the fact that HPV16 E6 in these cells promoted YAP
protein levels, which is evidenced in studies presented later in this
report.
The soft agar assay for colony formation was also used to deter-
mine whether high levels of YAP enhanced the transformed pheno-
type of cervical cancer cell lines. As shown in Fig 3C, HT3-YAPS127A
cells formed more colonies than HT3-YAP cells, while HT3-YAP
cells formed more colonies than HT3-MXIV cells. Similarly, ME180-
YAPS127A cells formed more colonies than ME180-YAP cells, while
ME180-YAP cells formed more colonies than ME180-MXIV cells
(Fig 3E). A fluorometric colony formation kit (CytoSelectTM 96-Well
Cell Transformation Assay kit, Cell Biolabs, Inc.) was used to avoid
the potential subjective results from manual colony counting. The
results clearly showed that HT3-YAPS127A (Fig 3D) and ME180-
YAPS127A cells (Fig 3F) had the highest anchorage-independent
growth rate, while the HT3-MXIV and ME180-MXIV control cells
had the lowest anchorage-independent growth rates (Fig 3D and F).
YAP enhances tumor growth in vivo
A mouse xenograft tumor model was used to determine the effects
of YAP on the progression of cervical cancer in vivo. The results
showed that in comparison with ME180-MXIV cells, tumors derived
from ME180-YAP and ME180-YAPS127A cells were larger and
detected earlier. On day 23 of tumor growth, the tumor volumes
(mm3, mean  SEM, n = 6) of the ME180-YAP group (952.5 
124.3) and the ME180-YAPS127A group (963.1  232.6) were signifi-
cantly larger than that of the ME180-MXIV group (236.8  23.4)
(P < 0.01) (Fig 4A–D). The weights of the tumors in the YAP and
YAPS127A groups were also significantly higher than those of the
control group (n = 6, P < 0.001, Fig 4E). Western blot analysis
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Figure 2. Effect of YAP on the proliferation of normal and cancerous
cervical cells.
A, C, E Western blot analysis showing levels of YAP and phosphorylated
YAP in ME180 cell lines [ME180-MXIV (control), ME180-YAP, and
ME180-YAPS127A cells] (A); HT3 cell lines [HT3-MXIV (control), HT3-YAP,
and HT3-YAPS127A cells] (C); and Ect1 cell lines [Ect1-MXIV (control),
Ect1-YAP, and Ect1-YAPS127A cells] (E). b-Actin was used as a protein
loading control.
B, D, F Growth curves of YAP-overexpressed ME180 cell lines [ME180-MXIV
(control), ME180-YAP, and ME180-YAPS127A cells] (B); HT3 cell lines
[HT3-MXIV (control), HT3-YAP, and HT3-YAPS127A cells] (D); and Ect1 cell
lines [Ect1-MXIV (control), Ect1-YAP, and Ect1-YAPS127A cells] (F). Each
point represents the mean  SEM (n = 4). ***P < 0.0001, ME180-
MXIV vs. ME180-YAP cells and ME180-MXIV vs. ME180-YAPS127A cells
on day 8. ***P < 0.0001, HT3-MXIV vs. HT3-YAP cells and HT3-MXIV vs.
HT3-YAPS127A cells on day 8. ***P < 0.0001, Ect1-MXIV vs. Ect1-Ect1-
YAPS127A cells on day 4. *P < 0.0074, Ect1-MXIV vs. Ect1-YAP cells on
day 4.
G Western blot showing YAP levels in non-targeting control siRNA
(siCtrl)- and YAP siRNA (siYAP)-transfected HT3 cells.
H Proliferation of HT3 cells treated with control (siCtrl) or YAP siRNA
(siYAP). Each point represents the mean  SEM (n = 5). ***P < 0.001
compared with siCtrl (siCtrl vs. siYAP, P = 0.0002).
Data information: Data in (B), (D), and (F) were analyzed for significance using
a one-way ANOVA in GraphPad Prism 5 with Tukey’s post hoc test. Data in (H)
were analyzed with an unpaired t-test in GraphPad Prism 5 with Welch’s
correction.
Source data are available online for this figure.
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Figure 3. Effect of YAP on the anchorage-independent growth of normal and cancerous cervical cells.
A Representative images showing colonies formed by Ect1-MXIV, Ect1-YAP, and Ect1-YAPS127A cells after growth in soft agar for 9 days. Scale bar: 500 lm.
B Quantitative data showing colony formation in Ect1-MXIV, Ect1-YAP, and Ect1-YAPS127A cells. Each bar represents mean  SEM of five independent experiments.
Bars with different letters are significantly different from each other (Ect1-MXIV vs. Ect1-YAP, P = 0.0003; Ect1-MXIV vs. Ect1-YAPS127A, P = 0.0002).
C, E Representative images showing the anchorage-independent growth of YAP-expressing HT3 (C) and ME180 (E) cervical cancer cell lines. Anchorage-independent cell
growth was determined by the soft agar colony formation assay. Scale bar: 500 lm.
D, F Fluorescence-based quantitative analysis showing the differences of anchorage-independent growth in HT3-MXIV, HT3-YAP, and HT3-YAPS127A (D) and ME180-MXIV,
ME180-YAP, and ME180-YAPS127A cells (F). The anchorage-independent cell growth was determined using a CytoSelect 96-Well Cell Transformation Assay kit, and
data are presented as relative fluorescent units (RFU). Each bar represents mean  SEM of four independent experiments. Bars with different letters are
significantly different from each other (HT3-MXIV vs. HT3-YAP, P = 0.0002; HT3-MXIV vs. HT3-YAPS127A, P < 0.0001; ME-MXIV vs. ME-YAP, P = 0.0011; ME-MXIV vs.
ME-YAPS127A, P = 0.0013).
Data information: Data in (B), (D), and (F) were analyzed for significance using one-way ANOVA in GraphPad Prism 5 with Tukey’s post hoc tests.
Source data are available online for this figure.
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confirmed the overexpression of YAP protein in both ME180-YAP
and ME180-YAPS127A tumor xenografts (Fig 4F). Fluorescent
immunohistochemistry clearly indicated that tumor tissues derived
from ME180-YAP and ME180-YAPS127A tumor xenografts had higher
expression of Ki67, a known cell proliferation marker, confirming
our in vitro observations that YAP regulates the proliferation of
cervical cancer cells in vivo (Fig 4G, Appendix Fig S8).
To further confirm that YAP plays a role in regulating the prolif-
eration of cervical cancer cells in vivo, we used lentivirus-based YAP
shRNAs to knock down YAP protein in ME180 cells. Non-targeting
shRNA was used as a control (shCtrl). Western blot analysis demon-
strated that YAP shRNAs successfully reduced total and phosphory-
lation of YAP protein level in ME180 cells (Fig 4H). Injection (SC) of
ME180-CTRL cells into the athymic nude mice induced tumor forma-
tion in 100% (6/6) of the mice within 2 weeks. However, injection
of the YAP-knockdown ME180-shYAP#1 cells into the nude mice
induced tumor formation in only one mouse (1/6). Moreover, the
tumor derived from ME180- shYAP#1 cells grew very slowly (Fig 4I
and J). These results indicated that YAP protein is essential for cervi-
cal tumor formation and tumor cell growth in vivo.
TGF-a, which is up-regulated by YAP, promotes proliferation of
cervical cancer cells
Amphiregulin (AREG), a known YAP target gene, was up-regulated
by YAP in cervical cancer ME180 cells (Figs 5A and EV2A). Most
importantly, overexpression or constitutive activation of YAP
induced significant increase in the secretion of AREG in the culture
medium (Fig EV2B). Knockdown of YAP significantly reduced
AREG concentrations in the culture medium (Fig EV2C). Interest-
ingly, overexpression of wild-type YAP or constitutively active YAP
also dramatically increased expression of TGF-a and EGFR mRNA
(Figs 5A and EV2A). This observation is supported by the RNA
sequencing data extracted from TCGA datasets, in which we found
that YAP expression is significantly correlated with TGF-a and EGFR
expression in cervical cancer (P = 0.0009 and P = 0.0122, respec-
tively, Fig EV3). Consistent with our observations in ovarian granu-
losa cell tumors (Wang et al, 2012a), TGF-a significantly enhanced
proliferation of ME180 cells (Fig 5B) and promoted cell cycle
progression (Fig 5C). Treatment of ME180 cells with TGF-a for 24 h
resulted in elongation of ME180 cells (Fig 5D). In growth medium,
control ME180 cells formed a monolayer upon reaching confluence
and had a marked reduction in growth rate. TGF-a-treated ME180
cells, however, continued to grow even after the cells reached
confluence, leading to the formation of multilayer cell plaques
(Fig 5D). Wound-healing assays showed that TGF-a (10 h) treat-
ment dramatically induced wound closure in ME180 cells, indicating
that TGF-a also induced cervical cancer cell migration (Fig 5E).
The Hippo signaling pathway interacts with TGF-a/EGFR signaling
to regulate cervical cancer cell proliferation and migration
TGF-a treatment induced multilayer growth of ME180 cells, a
phenotype that was observed in ME180 cells transfected with
constitutively activated YAP (Fig 5), suggesting potential involve-
ment of the Hippo pathway in this process. Treatment of ME180
cells with TGF-a resulted in a rapid increase in the phosphorylation
of the EGFR and activation of the PI3K and MAPK signaling path-
ways (Fig 6A). TGF-a also rapidly suppressed phosphorylation of
YAP at serine 127 and serine 397 in ME180 cells (Fig 6A and B,
Appendix Fig S9A). The ability of TGF-a to suppress YAP phospho-
rylation was also observed in HT3 and End1 cells (Appendix
Fig S10). Moreover, LATS1 and MOB1 were dephosphorylated by
TGF-a treatment (Fig 6B, Appendix Fig S9B and C). Dephospho-
rylation of LATS1/2 and MOB1 results in the dissociation of LATS1/
2-MOB1 complex, leading to suppression of the Hippo signaling
pathway and activation of YAP (Pan, 2010; Yu & Guan, 2013). These
observations indicate that the EGFR pathway interacts with the
Hippo pathway to regulate the proliferation of cervical cancer cells.
To further confirm that TGF-a treatment increases YAP transcrip-
tional activity, we determined the mRNA level of amphiregulin
(AREG), a known YAP target gene (Zhang et al, 2009; Hong et al,
2014). qRT-PCR analysis showed that AREG mRNA levels in ME180-
YAP and ME180-YAPS127A cells were increased by 2.9- and 6.8-fold,
respectively, compared to ME180-MXIV control cells (Fig 6C). Treat-
ment of ME180 cells with TGF-a led to a 40-fold increase in AREG
mRNA (Fig 6C). Knockdown of YAP significantly suppressed TGF-
a-stimulated expression of AREG mRNA (Fig 6D). RNA sequencing
▸Figure 4. Effect of YAP on human cervical tumor growth in vivo.A, B Representative images of tumor xenografts of ME180-MXIV (MX, right flank), ME180-YAP (A) (YAP, left flank), and ME180-YAPS127A (B) (YAPS127A, left flank) cells
implanted in athymic nude mice. Red lines indicate the edge of tumors.
C The growth curve of human tumor xenografts derived from control (ME-MX) and YAP-overexpressing ME180 cervical cancer cell lines (ME-YAP, ME-YAPS127A)
implanted in the athymic nude mice. Each point represents mean  SEM of six tumors (control n = 10).
D Representative images showing the relative size of tumors from control and YAP-overexpressing ME180 cervical cancer cells.
E The average weight of tumor xenografts from the control and YAP-overexpressing ME180 cell lines. Data were analyzed for significance using one-way ANOVA in
GraphPad Prism 5 with Tukey’s post hoc tests. Each bar represents the mean  SEM (n = 10 for control, n = 6 for YAP and YAPS127A groups). Bars with different
letters are significantly different from each other (MXIV vs. YAP, P = 0.0008; MXIV vs. YAPS127A, P < 0.0001).
F Western blot analysis of YAP protein levels in the tumor xenografts derived from ME180-MXIV, ME180-YAP, and ME180-YAPS127A cells.
G Expression of Ki67 in the tumor xenografts of ME180-MXIV, ME180-YAP, and ME180-YAPS127A cells implanted in athymic nude mice. Ki67 was visualized using an
Alexa-488 (green)-conjugated secondary antibody. Actin was visualized using an Alexa-594 (red)-conjugated secondary antibody. Nuclei were stained with DAPI.
Scale bar: 20 lm. Note the significant increase in the Ki67-positive cells in the ME180-YAP and ME180-YAPS127A tumor xenografts.
H Western blot analysis showing YAP protein levels in ME180 cells transfected with lentiviral empty vector (shCtrl) or lentivirus-based YAP shRNAs (shYAP#1 or
shYAP#2).
I Representative images showing tumor xenografts derived from ME180-shCtrl cells (left flank) and ME180-shYAP#1 cells (right flank) (n = 6).
J Representative images showing the relative size of tumors derived from ME180 cervical cancer cells transfected with control shRNA (left, shCtrl) or YAP shRNA#1
(right, shYAP#1) (n = 6).
Source data are available online for this figure.
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data extracted from TCGA datasets also showed that TGF-a mRNA
level was significantly correlated with AREG mRNA expression in
cervical cancer (P = 0.0003, Fig EV3). This evidence clearly
suggests that in cervical cancer cells, the TGF-a/EGFR pathway
interacts with the Hippo/YAP signaling pathway to form an auto-
crine/paracrine loop, which may play critical role in regulating
cervical cancer progression.
Experiments were performed to determine whether the signaling
pathways activated by TGF-a would affect the phosphorylation of
YAP. Treatment of ME180 cells with EGFR inhibitor AG1478
completely prevented the TGF-a-induced dephosphorylation of YAP
(Appendix Fig S11). Treatment with the PI3K inhibitor LY294002 or
the MEK inhibitor U0126 partially but significantly blocked TGF-a-
stimulated YAP protein dephosphorylation, suggesting that the
EGFR/PI3K and EGFR/MEK/ERK signaling pathways are involved
in mediating the actions of TGF-a on the Hippo pathway in cervical
cancer (Appendix Fig S11).
To determine whether YAP plays a role in TGF-a-stimulated
growth of cervical cancer cells, we knocked down the expression of
YAP in ME180 cells using siRNA and then treated these cells with
TGF-a. Results showed that TGF-a promoted ME180 cell prolifera-
tion in the control group, but it failed to do so in the YAP-knock-
down ME180 cells (Fig 6E). Moreover, knockdown of YAP in
ME180 cells diminished TGF-a-stimulated ME180 cell migration, as
indicated by the significant decrease in the wound closure in YAP-
knockdown ME180 cells after TGF-a treatment (Fig 6F, Appendix
Fig S12). Taken together, these results indicate that the effects of
TGF-a on cervical cancer cell proliferation and migration require, at
least in part, via activation of YAP protein.
AREG activates YAP protein and induces cervical cancer cell
growth
We found that TGF-a treatment and YAP overexpression signifi-
cantly increased AREG mRNA level (Fig 6). Since AREG is a
member of the family of the EGF-like ligands and we have shown
that the EGFR pathway interacts with the Hippo pathway to regulate
cervical cancer cell growth, we infer that AREG may also be
involved in the regulation of cervical cancer cell proliferation. Treat-
ment of ME180 cells with recombinant human AREG increased
phosphorylation of EGFR at Tyr1173 and reduced phosphorylation
of YAP (at Ser127 and Ser397), LATS1 (Ser 909), and MOB1 (Thr35)
within 30 min (Fig 7A, Appendix Fig S13). Treatment of ME180
cells with AREG induced elongated cell morphology (within 24 h)
and significantly increased cell proliferation (72 h) (Fig 7B). More-
over, AREG potently stimulated ME180 cell migration, as indicated
by the significant increase in the wound closure in the wound-heal-
ing assay (Fig 7C). Most interestingly, we found that the AREG
mRNA expression was induced by AREG itself in cultured ME180
cervical cancer cells (Fig 7D). Knockdown of YAP with YAP siRNA
significantly suppressed AREG-stimulated AREG mRNA expression
(P < 0.0001) (Fig 7E).
The interaction between the Hippo/YAP and the EGFR signaling
pathways regulates cervical cancer cell growth
Treatment of confluent cervical cells with TGF-a and AREG resulted
in a rapid and significant decrease in phosphorylation of LATS1,
MOB1, and YAP (Figs 6A and B and 7A, Appendix Figs S9, S10 and
S13), suggesting that the Hippo pathway may involve in the YAP
and EGFR signaling interaction. LATS1 and LATS2 are main compo-
nents of the Hippo pathway and can directly phosphorylate YAP at
Ser127. Knockdown of LATS1/2 in ME180 cells with LATS1/2
siRNAs activated YAP, which is indicated by a significant decrease
in phospho-YAP (S127) (Fig EV4A). Knockdown of LATS1/2 in
ME180 cells also significantly increased cell proliferation and
enhanced anchorage-independent cell growth (Fig EV4B and C).
The advantage of 3D culture, especially its high physiological rele-
vance, has been reported (Friedrich et al, 2009). We found that
knockdown of LATS1/2 significantly induced cell growth in the 3D
culture system (Fig 8A and B). Importantly, knockdown of LATS1/2
significantly increased the AREG secretion in both 2D and 3D
culture (Fig EV4D and E). Consistent with 2D culture results, treat-
ment of ME180 cells with AREG also significantly stimulated cell
growth in the 3D culture system (Fig 8C and E).
Both TGF-a and AREG specifically bind to EGFR to regulate cell
proliferation. Knockdown of EGFR inhibits basal and YAP-induced
growth of ME180 cell (Fig EV5A and B). Most importantly, knock-
down of EGFR significantly reduced basal and YAP-induced secre-
tion of AREG (Fig EV5C). In addition, the involvement of EGFR
pathway in YAP regulating cervical cancer cell growth is further
evidenced by the observation that treatment of ME180-YAP and
ME180-YAPS127A cells with AG1478 (EGFR inhibitor) dramatically
blocked their ability to form colonies in the soft agar (Fig 8D). We
also found that verteporfin, an antagonist of YAP (Liu-Chittenden
et al, 2012), not only suppressed the colony formation of ME180-MXIV,
ME180-YAP, and ME180-YAPS127A cells (Fig 8D), but also reduced
the production of AREG in these cells (Fig EV5C).
▸Figure 5. YAP stimulates expression of EGF-like ligands and EGFR in cervical cancer cell to promote cervical cancer cell proliferation and migration.A RT–PCR results showing that YAP stimulates the mRNA expressions of EGFR, AREG, and TGF-a in ME180 cervical cancer cell. Data were analyzed for significance
using one-way ANOVA in GraphPad Prism 5 with Tukey’s post hoc tests. Each bar represents mean  SEM (n = 4). Bars with different letters are significantly different
from each other (YAP mRNA: MXIV vs. YAP, P = 0.0003; MXIV vs. YAPS127A, P = 0.0001; EGFR mRNA: MXIV vs. YAP, P = 0.0066; MXIV vs. YAPS127A, P = 0.0003; TGF-a
mRNA: MXIV vs. YAP, P = 0.0235; MXIV vs. YAPS127A, P = 0.0040; AREG mRNA: MXIV vs. YAP, P = 0.0002; MXIV vs. YAPS127A, P < 0.0001).
B Proliferation of ME180 cells incubated in medium containing 1% FBS in the absence (control) or presence of 10 ng/ml TGF-a. Data were analyzed with unpaired
t-test in GraphPad Prism 5 with Welch’s correction. Each point represents the mean  SEM of four independent repeats. ***P < 0.0001 versus control on day 5.
C TGF-a treatment (10 ng/ml, 24 h) promotes ME180 cell cycle progression. G1, S, and G2 indicate cells in G1 phase, DNA synthesis phase, and the G2/M phase,
respectively, of cell cycle. Apo: apoptotic cells.
D Representative images showing the morphology of ME180 cells with or without TGF-a (10 ng/ml) treatment for 24 h (scale bar: 50 lm) or 108 h (scale bar: 25 lm).
Please note the elongation of ME180 cells after TGF-a treatment for 24 h (TGF-a, 24 h) and the formation of multiple layers in ME180 cells after TGF-a treatment for
108 h (TGF-a, 108 h).
E Effect of TGF-a on the migration of ME180 cells. TGF-a treatment (100 ng/ml, 10 h) drastically stimulated the migration of ME180 cells.
Source data are available online for this figure.
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On the soft agar, ME180-YAP and ME180-YAPS127A cells formed
much more, larger and fast-growing colonies in comparison with
ME180-MXIV cells (Figs 3C and 8D). We observed that colonies
derived from ME180-YAPS127A and ME180-YAP cells are somewhat
resistant to AG1478 or verteporfin treatment. However, combined
treatment with verteporfin and AG1478 completely blocked the
growth of ME180-YAPS127A cells on soft agar, suggesting that the
combined targeting of the Hippo/YAP and EGFR pathways may be a
more efficient way to inhibit cervical cancer cell growth (Fig 8D).
We then used a more physiology-relevant 3D culture system to
examine our finding. ME180 cervical cancer cells were loaded onto
the 3D culture system and incubated for 3 days to form spheroids.
The formed spheroids were treated with verteporfin or/and AG1478
for 6 days. We found that AG1478 treatment resulted in scattered
distribution of ME180 cells and incompletely formed spheroids, indi-
cating that blockade of EGFR could partially disrupt cervical cancer
cell–cell communication (Fig 8E). Verteporfin treatment completely
blocked cancer cell growth and disrupted cervical cancer cell–cell
communication, leading to the destruction of initially formed spher-
oids (Fig 8E). Combined treatment with AG1478 and verteporfin
also completely blocked the formation of spheroids in the 3D hanging-
drop culture system (Fig 8E).
YAP is involved in HPV E6 regulation of cervical cancer
cell growth
Epidemiological studies have shown that the high-risk HPV E6/E7
protein plays a critical role in the initiation and progression of cervi-
cal cancer. However, the exact molecular mechanism underlying the
ability of high-risk HPV E6/E7 to regulate cervical cancer is largely
unknown. Treatment of HT3 cells (cervical cancer cells without
HPV infection) (Fogh et al, 1977; Yee et al, 1985) with HPV16 E6
protein significantly increased cancer cell growth (Fig 9A). Surpris-
ingly, treatment of HT3 cells with HPV16 E6 increased protein levels
of total YAP and phosphorylated YAP (Ser127), but had no effect on
the protein level of b-actin (Fig 9B). Real-time PCR results showed
that treatment of HT3 cells with HPV16 E6 for 48 h also significantly
increased mRNA level of AREG (Fig 9C). This finding is consistent
with the observed increase in YAP protein levels since AREG is
downstream gene of the Hippo/YAP pathway. Knockdown of YAP
with YAP siRNA eliminated HPV16 E6-stimulated HT3 cell prolifera-
tion (Fig 9D and E), further suggesting that YAP is an important
mediator of HPV16 E6 action in cervical cancer cells.
Since HeLa cells express endogenous HPV18 E6 protein, we used
this cell line to determine whether YAP also mediates the action of
endogenous HPV E6 protein. Knockdown of HPV18 E6 with specific
siRNA not only decreased E6 mRNA level, but also reduced YAP
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Figure 6. TGF-a regulates the Hippo signaling pathway in cervical cancer
cells.
A Western blot analysis showing effects of TGF-a on phosphorylation of
EGFR, YAP, AKT, and ERK1/2. ME180 cells were starved for 6 h after
reaching cell confluence, then cells were treated with TGF-a (100 ng/ml)
for 0, 5, 10, 30, 60 or 120 min.
B Western blot analysis showing effects of TGF-a on the phosphorylation of
the components of the Hippo signaling pathway. ME180 cells were starved
for 6 h after reaching cell confluence, then cells were treated with TGF-a
(100 ng/ml) for 0, 30, 60 min.
C Real-time PCR determines the action of TGF-a and YAP levels on the mRNA
expression of AREG. Each bar represents the mean  SEM (n = 5). Bars
with different letters are significantly different from each other (Ctrl vs.
TGF-a, P < 0.0001; MXIV vs. YAP, P < 0.0001; MXIV vs. YAPS127A,
P < 0.0001).
D Real-time PCR analysis showing that knockdown of YAP with YAP siRNA
(siYAP) significantly suppressed TGF-a-induced (FBS 10%, TGF-a: 10 ng/ml
for 48 h) AREG expression in ME180 cells. siCTRL, a non-targeting siRNA,
was used as a negative control. Each bar represents the mean  SEM
(n = 5). Bars with different letters are significantly different from each
other (siCTRL vs. siCTRL+TGF-a, P < 0.0001; siYAP+CTRL vs. siYAP+TGF-a,
P < 0.0001; siCTRL+TGF-a vs. siYAP+TGF-a, P = 0.0067).
E Proliferation of ME180 cells (FBS 1%) treated with control (siCTRL) or YAP
(siYAP) prior to treatment with control medium or TGF-a (10 ng/ml) for
108 h. Each bar represents the mean  SEM (n = 4). Bars with different
letters are significantly different from each other (siCtrl vs. siCTRL+TGF-a,
P = 0.0058; siYAP+CTRL vs. siYAP+TGF-a, P = 0.1840; siCTRL+TGF-a vs.
siYAP+TGF-a, P = 0.0013).
F Quantitative data of the wound-healing assay showing the migration of
ME180 cells that were treated with control (siCTRL) or YAP siRNA (siYAP)
prior to treatment with or without TGF-a for 12 h. Each bar in bar graphs
represents the mean  SEM (n = 4). Bars with different letters are
significantly different from each other (siCtrl vs. siCTRL+TGF-a, P < 0.0001;
siYAP+CTRL vs. siYAP+TGF-a, P < 0.0001; siCTRL+TGF-a vs. siYAP+TGF-a,
P = 0.0041).
Data information: Data in (C–F) were analyzed for significance using one-way
ANOVA in GraphPad Prism 5 with Tukey’s post hoc tests.
Source data are available online for this figure.
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protein levels (Fig 9F), suppressed AREG mRNA expression
(Fig 9G), and inhibited HeLa cell proliferation (Fig 9H). Moreover,
knockdown of HPV18 E6 decreased AREG secretion in HeLa cells
(Fig 9I). Knockdown of YAP reduced YAP protein (Fig 9F),
suppressed AREG mRNA expression (Fig 9G), and inhibited HeLa
cell proliferation (Fig 9H). Knockdown of YAP had no effect on the
mRNA level of HPV18 E6 (Fig 9F). These results suggested that both
recombinant and endogenous HPV E6 proteins were able to increase
YAP protein levels.
HPV E6 prevents YAP protein from degradation
The HT3 cancer cell line, which is HPV negative (Fogh et al, 1977;
Yee et al, 1985), was used to determine the mechanism underlying
HPV16 E6 regulation of YAP protein level. Treatment of HT3 cells
with HPV16 E6 increased YAP protein (Fig 9B and D), but HPV16
E6 did not affect YAP mRNA expression (Fig 10A and B). This
suggests that HPV16 E6 may regulate YAP protein turnover. Treat-
ment of HT3 cells with MG132, a potent proteasome inhibitor, for
4 h or 8 h drastically increased YAP and EGFR protein levels
(Fig 10C). In contrast, treatment of HT3 cells with cycloheximide
(CHX), an inhibitor of eukaryotic gene translation, for 4 h or 8 h
significantly reduced EGFR and YAP protein levels (Fig 10C and D).
This evidence suggests that YAP and EGFR proteins are continu-
ously synthesized and degraded in a proteasome-dependent mecha-
nism in cervical cancer cells. The addition of HPV16 E6 prevented
the degradation of YAP protein in CHX-treated cells, but had little or
no effect on the degradation of EGFR (Fig 10D and E). These obser-
vations clearly indicate that HPV16 E6 stabilizes the YAP protein in
cervical cancer cells.
To explore the mechanisms underlying HPV E6 stabilizing
YAP protein, we transfected HT3 cells with lentivirus empty
control vector (Ctrl) or lentivirus-based HPV16 E6-expressing
vector and established HT3-CTRL and HT3-E6 cell lines. Western
blotting results indicated that expression of E6 in HT3 cells also
increased the proteins level of total YAP and Ser127-phosphory-
lated YAP (Fig 10F), but dramatically decreased Ser397-phospho-
rylated YAP (Fig 10F). It has been reported that phosphorylation
of YAP (YAP protein isoform 1) at Ser397 (corresponds to
Ser381 in YAP protein isoform 2) primes YAP for subsequent
phosphorylation by CK1d/e, leading to b-TrCP (SCF) ubiquitin
ligase-dependent proteolytic degradation of YAP protein (Zhao
et al, 2010). Surprisingly, we found that expression of E6 in HT3
cells had little or no effect on the b-TrCP and LATS1/2, but it
increased the protein level of CK1d/e (Fig 10F). The HPV E6-
induced decrease in p-YAP (S397) and increase in CK1d/e
suggested that the CK1d/e may not be actively involved in HPV
E6 stabilization of YAP protein.
Hong et al (2014) recently suggested SOCS6 can directly bind to
YAP and induce YAP degradation. Interestingly, we found that
expression of HPV16 E6 reduced the protein level of SOCS6 in HT3
cells. Knockdown of HPV18 E6 increased the protein level of SOCS6
in HeLa cells (Fig 10F and G). These results indicate that SOCS6
may play a role in HPV E6-mediated stabilization of YAP. To con-
firm our finding, we knocked down SOCS6 in HT3 cells using SOCS6
siRNAs. Western blot analysis demonstrated that knockdown of
SOCS6 increased total YAP and phosphorylation of YAP at Ser127
levels, but decreased phosphorylation of YAP at Ser397 (Fig 10H).
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Figure 7. Function and expression of AREG in cervical cancer cells.
A Western blot analysis showing that AREG treatment induced
dephosphorylation of LATS1, MOB1, and YAP. ME180 cells were starved for
6 h after reaching cell confluence, then cells were treated with AREG
(50 ng/ml) for 0, 30, 60 min.
B AREG (50 ng/ml) treatment induced appearance of elongated cells in
ME180 cells (top and middle panels) and significantly stimulated ME180
cell proliferation (lower panel). Each bar represents mean  SEM (n = 5).
Bars with different letters are significantly different from each other
(P = 0.003). Scale bar: 100 lm.
C Wound-healing assay showing that AREG stimulates migration of
ME180 cervical cancer cells within 10 h in serum-free medium. Scale bar:
200 lm.
D Real-time PCR showing that treatment of ME180 cells with AREG for 24 h
significantly increased AREG mRNA expression. Each bar represents
mean  SEM (n = 9). Bars with different letters are significantly different
from each other (P < 0.0001).
E Real-time PCR showing that knockdown of YAP in ME180 cells with YAP
siRNA (siYAP) significantly suppressed AREG-induced AREG mRNA
expression. siCTRL (non-target siRNA) was used as a siRNA control. Each
bar represents mean  SEM (n = 4). Bars with different letters are
significantly different from each other (siCTRL vs. siCTRL+AREG, P < 0.0001;
siYAP+CTRL vs. siYAP+AREG, P < 0.0001; siCTRL+AREG vs. siYAP+AREG,
P = 0.0037).
Data information: Quantitative data in (B) and (D) were analyzed for
significance using unpaired t-test in GraphPad Prism 5 with Welch’s
correction. Data in (E) were analyzed for significance using one-way ANOVA in
GraphPad Prism 5 with Tukey’s post hoc tests.
Source data are available online for this figure.
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Figure 8. The Hippo/YAP and the ERBB pathways interact with each other to regulate cervical cancer cell growth.
A Representative images showing the morphology of spheroids derived from ME180-siCtrl and ME180-siLATS1/2 cells growing in a 3D hanging-drop culture system for
10 days. Scale bar: 1.0 mm.
B Quantitative data showing changes in the volume of spheroids derived from ME180-siCTRL and ME180-siLATS1/2 cells growing in a 3D hanging-drop culture system.
Each bar represents mean  SEM (n = 5). Bars with different letters are significantly different from each other (P = 0.0004).
C Quantitative data showing changes in the volume of spheroids derived from ME180 cells growing in a 3D hanging-drop culture system in the absence or presence of
AREG (20 ng/ml, 8 days). Each bar represents mean  SEM (n = 5). Bars with different letters are significantly different from each other (P = 0.0030).
D Soft agar assay showing the effect of AG1478 and VTPF on colony formation in ME180-MXIV, ME180-YAP and ME180-YAPS127A cells. Scale bar: 500 lm.
E Representative images showing the effect of AREG, EGFR inhibitor (AG1478), and YAP antagonist verteporfin (VTPF) on the growth of ME180 cell in a 3D hanging-drop
culture system. ME180 cells were incubated in the 3D hanging-drop culture system for 10 days in the absence or presence of AREG, AG1478 or verteporfin for 8 days.
Scale bar: 1.0 mm.
Data information: Quantitative data in (B) and (C) were analyzed for significance using unpaired t-test in GraphPad Prism 5 with Welch’s correction.
Source data are available online for this figure.
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Clearly, SOCS6 is actively involved in HPV E6 stabilizing YAP
protein in the cervical cancer cells.
YAP expression in HPV16 E6/E7-induced mouse cervical
tumors and HPV16-containing human foreskin keratinocytes
“raft” cultures
Transgenic mouse models were used to determine whether HPV E6
also effects YAP protein level in vivo. Previous studies showed that
HPV16-E6 or HPV16-E6/E7 double-transgenic mice treated for
6 months with estrogen can develop cervical cancers (Brake &
Lambert, 2005; Shai et al, 2007). Consistent with our results, we
found that in comparison with the control mouse cervical tissues
(Fig 11A and B), YAP is highly expressed in the E6 (Fig 11C and D)
and E6/E7-induced cervical tumor tissues (Fig 11E and F) and YAP
is mainly localized to nucleus of tumor cells (Fig 11D and F).
The HPV16-containing organotypic human foreskin keratinocyte
(HFK) “raft” culture system provides an unique model to investigate
the life cycle of HPV16 (Lambert et al, 2005; Wang et al, 2009). We
used the HFK raft culture system to confirm whether the wild-type
HPV16 also affects YAP protein levels in HFKs, which share many
similar features with the basal epithelial cells in the cervical epithe-
lia. IHC staining results showed that keratinocytes in HPV16 plas-
mid-containing raft cultures were hyperproliferative compared with
cells in HPV-free HFK raft cultures (control) (Fig 11G and H). More
importantly, we found that YAP signal intensity in keratinocytes in
HPV16-containing raft cultures was much higher in comparison
with that of control (Fig 11G–J). Moreover, our results showed that
the majority of the YAP immunosignal was localized to the mid- to
upper spinous cells, with relatively lower signals observed in basal
and parabasal cells (Fig 11H). The expression level and distribution
of YAP in the HPV16-containing organotypic HFK raft culture
system perfectly match the YAP expression pattern and HPV DNA
distribution that are consistently observed in naturally occurring
HPV lesions (Stoler & Broker, 1986; Xiao et al, 2014).
Discussion
Epidemiological and molecular evidence indicates that high-risk
HPV, especially HPV type 16 and type 18, plays a causative role in
cervical cancer (Jemal et al, 2011). However, the molecular mecha-
nism(s) underlying HPV initiation of cervical cancer remains
unclear. Moreover, in HPV-infected patients, the majority of HPV-
associated lesions regress spontaneously (Melnikow et al, 1998),
indicating that additional genomic alterations are also necessary for
transformation of cervical epithelial cells and progression of cervical
cancer. The present study provides compelling evidence showing
that the HPV E6 protein, the Hippo pathway, and the EGFR signaling
pathway interact with each other to regulate cervical cancer
progression.
Yes-associated protein is the major downstream effector of the
Hippo pathway. Activation of the Hippo pathway results in phos-
phorylation and sequestration of YAP into the cytoplasm, leading to
inactivation of YAP-regulated gene transcription (Fernandez et al,
2009; Pan, 2010). Elevated YAP expression and nuclear localization
have been observed in multiple types of human cancers, including
liver cancer, colon cancer, epithelial ovarian cancer, lung cancer,
and prostate cancer (Overholtzer et al, 2006; Zender et al, 2006;
Dong et al, 2007; Yuan et al, 2008; Zhang et al, 2009; Hall et al,
2010; Jemal et al, 2011; Hergovich, 2012; He et al, 2015). In liver
cancer, YAP has been reported to be an independent prognostic
marker for overall survival and disease-free survival (Xu et al,
2009). In epithelial ovarian cancer, research has shown that a high
level of nuclear YAP is strongly associated with poor patient
survival (Hall et al, 2010). Up to date, only one IHC study showed
that YAP could function as a predictive marker for cervical cancer
(Xiao et al, 2014). The role of YAP in cervical cancer is unclear. In
the present study, we show that YAP is overexpressed in the cervi-
cal cancer tissues. Moderate/strong expression of YAP protein was
observed in 91% of cervical cancer tissues, while moderate/strong
expression of YAP protein was not observed in all 10 normal cervi-
cal tissues (Table 1). Moreover, YAP expression was significantly
correlated with the FIGO stage, the extent of tumor, and the degree
of regional lymph node involvement. To verify the clinical relevance
of YAP up-regulation in the cervical cancer, we performed a cross-
cancer YAP gene alteration analysis by using the multidimensional
cancer genomic datasets and online analysis tools. We surprisingly
found that among all cancer types, cervical cancer has the highest
frequency of YAP gene alterations. The subsequent network analysis
indicated that many cell proliferation-associated genes that inter-
acted with YAP were up-regulated in various degrees in examined
cervical cancer cases. Our data provide evidence that YAP could be
used as a potential prognostic biomarker for cervical cancer. Since
we do not have patient survival data, we cannot correlate YAP
expression data with cervical patient survival in the present study.
However, the high level of expression and nuclear location of YAP
protein in cervical cancer tissues, as well as the very high frequency
of YAP gene amplification in the patient samples, strongly argue that
YAP plays an important role in regulating the progression of cervical
cancer.
The concept that YAP plays a role in regulating the progression
of cervical cancer is further supported by the following evidence: (i)
Knockdown of YAP significantly reduced the growth rate of ME180,
HT3, and HeLa human cervical cell lines in vitro and suppressed
cervical cancer tumorigenesis in vivo; (ii) ectopic expression of
wild-type YAP or constitutively active YAP in cervical cancer cells
significantly stimulated cancer cell growth in vitro; (iii) overexpres-
sion or constitutive activation of YAP in cervical cancer cells
overcame the contact inhibition-induced cell growth inhibition; (iv)
overexpression or constitutive activation of YAP in cervical cancer
cells promoted cell cycle progression; and (v) finally, overexpres-
sion or constitutive activation of YAP in cervical cancer cells
dramatically stimulated tumor growth in vivo. As we have shown in
this study, YAP is overexpressed and localized to the nucleus of the
cancer cells in the cervical cancer tissues. According to our in vitro
and in vivo data, high levels of biologically active YAP protein in the
nucleus of cervical cancer cells are expected to stimulate cancer cell
proliferation and promote cervical cancer progression.
Notably, under low-density cell culture conditions, knockdown
of YAP had no significant effect on the growth of cervical cancer
cells incubated in complete medium (with 10% FBS). After the
cultured cells achieved higher density, cell growth rate in the YAP-
knockdown group decreased, while cells in the control group
continued to proliferate. This result is consistent with the observa-
tion that when incubated in complete medium, ME180-YAPS127A,
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ME180-YAP, and ME180-MXIV cells had similar growth rates before
reaching confluence. However, after the cells reached confluence,
the ME180-YAPS127A and ME180-YAP cells continued to grow, while
the proliferation of ME180-MXIV cells almost stopped. These find-
ings indicate that YAP may play a critical role in overcoming cell
contact-induced inhibition of cell growth. Interestingly, under
serum-reduced culture conditions (with 1% FBS), ME180-YAPS127A
and ME180-YAP cells have a significantly higher growth rate in
comparison with ME180-MXIV cells (P < 0.001), regardless of the
cell density. The compensatory activity of YAP on cell growth with
serum deprivation suggests that YAP may control the production of
certain hormones or growth factors that are essential for the growth
of cervical cancer cells.
The present study indicates that TGF-a and AREG are the candi-
date growth factors. The Hippo/YAP signaling pathway interacts
with the ERBB signaling pathway to regulate cervical cancer cell
proliferation and migration. This concept is supported by the follow-
ing evidence: (i) Ectopic expression of wild-type YAP or constitutive
active YAP in cervical cancer cells not only significantly stimulated
TGF-a, AREG, and EGFR mRNA expression, but also induced AREG
secretion; (ii) knockdown of LATS1/2, the major suppressor of YAP,
stimulated secretion of AREG; (iii) TGF-a and AREG, via activation
of EGFR, stimulated proliferation, promoted cell cycle progression,
and enhanced migration of cervical cancer cells; (iv) TGF-a
suppressed the Hippo signaling pathway, which was demonstrated
by the significant reductions in the phosphorylation of LATS1,
MOB1, and YAP after TGF-a treatment; (v) treatment of cervical
cancer cell with TGF-a induced 40-fold increases in the transcription
of AREG, a known downstream target of the Hippo/YAP signaling
pathway (Zhang et al, 2009; Yu & Guan, 2013); and (vi) knockdown
of YAP eliminated TGF-a-induced proliferation and migration of
cervical cancer cells. Knockdown of YAP also suppressed TGF-a-
induced AREG transcription in cervical cancer cells. We also found
that AREG significantly stimulated cervical cancer cell proliferation
and promoted cancer cell migration. Intriguingly, AREG was able to
suppress phosphorylation of LATS1, MOB1, and YAP in the cervical
cancer cells, suggesting that AREG is not only a downstream target
of the Hippo pathway, but also an important upstream regulator of
the Hippo/YAP signaling pathway. Remarkably, we found that treat-
ment of cervical cancer cells with AREG resulted in a fourfold
increase in the expression of AREG mRNA (P > 0.001). Further-
more, blocking EGFR activity with AG1478, or knockdown of EGFR
using siEGFR, eliminated YAP-induced cell proliferation and AREG
secretion of cervical cancer cells. These observations, together with
previous results, provide convincing evidence for the existence of
an AREG/EGFR/Hippo signaling pathway/YAP/AREG autocrine
loop in cervical cancer cells, which may play a critical role in the
progression of cervical cancer (Fig 12). Of relevance to our findings
are previous reports showing that EGFR is overexpressed in cervical
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Figure 9. YAP is involved in HPV-E6 regulation of cervical cancer cell
growth.
A Effect of recombinant HPV16 E6 protein on the proliferation of HT3 cells.
Each point represents mean  SEM (n = 5). ***P = 0.0001 compared with
control (Ctrl) on day 4. HT3 cells were cultured in serum-reduced medium
in the presence or absence of recombinant HPV16 E6 (400 nM).
B Recombinant HPV16 E6 protein increased YAP protein level, but had no
effect on b-actin protein level in HT3 cells. Cell culture and treatment
procedure are the same as described in (A).
C AREG mRNA levels in HT3 cells incubated for 48 h with or without
recombinant HPV E6. Each bar represents mean  SEM (n = 5). Bars with
different letters are significantly different from each other (P = 0.0042).
D Western blotting analysis showing the effect of HPV16 E6 (400 nM, 48 h)
on YAP protein levels in HT3 cells transfected with non-targeting control
siRNA (siCtrl) or YAP siRNA (siYAP).
E Effect of YAP on HPV16 E6 stimulation of HT3 cell proliferation. siCtrl: non-
targeting control siRNA; siYAP: YAP siRNA; E6: 400 nM recombinant HPV16
E6, 48 h. Each bar represents mean  SEM (n = 4). Bars with the same
letters are not significantly different from each other (siCtrl vs. siCtrl+E6,
P = 0.0232; siCtrl+E6 vs. siYAP+E6, P = 0.0011).
F Knockdown of endogenous E6 in HeLa cells with HPV18 E6 siRNA (siE6)
reduced YAP protein in HeLa cells, while knockdown of YAP with YAP siRNA
(siYAP) in these cells had no effect on the mRNA level of HPV18 E6. siCtrl:
non-targeting control siRNA.
G Knockdown of endogenous HPV18 E6 in HeLa cells with HPV18 E6-specific
siRNA (siE6) significantly suppressed mRNA expression of AREG. Each bar
represents mean  SEM (n = 4). Bars with different letters are significantly
different from each other (siCtrl vs. siHPV18E6, P = 0.0181; siCtrl vs. siYAP,
P = 0.0005).
H Knockdown of endogenous HPV18 E6 in HeLa cells with HPV18 E6-specific
siRNA (siE6) significantly suppressed cell growth (n = 9, siCtrl vs.
siHPV18E6, P = 0.0002; siCtrl vs. siYAP, P = 0.0004).
I Concentrations of AREG in the culture medium of HeLa cells transfected
with non-targeting control siRNA (siCTRL) or HPV18 E6 siRNA (siHPV18E6).
Each bar represents mean  SEM (n = 6). Bars with different letters are
significantly different from each other (P = 0.0461).
Data information: Quantitative data in (A), (C), and (I) were analyzed for
significance using unpaired t-test in GraphPad Prism 5 with Welch’s
correction. Data in (E), (G), and (H) were analyzed for significance using one-
way ANOVA in GraphPad Prism 5 with Tukey’s post hoc tests.
EMBO Molecular Medicine Vol 7 | No 11 | 2015 ª 2015 The Authors
EMBO Molecular Medicine Role of Hippo/YAP pathway in cervical cancer Chunbo He et al
1440
cancer and is associated with poor prognosis and decreased survival
of cervical cancer patients (Schrevel et al, 2011; Soonthornthum
et al, 2011). The existence of this feedback loop in human cervical
cancer and its clinical relevance were further evidenced by the
results derived from multidimensional cancer genomic data analy-
sis. These analyses indicate that ~81% of human cervical cancer
cases have alterations in genes involved in this positive feedback
loop (Fig 12B). The synergetic suppressive effect of AG1478 and
verteporfin on the growth of ME180-YAP and ME180-YAPS127A cells
and secretion of AREG clearly indicates that combined targeting of
Hippo/YAP and EGFR pathways may represent a novel therapeutic
strategy for cervical cancer (Figs 8 and EV5).
Since Hippo-independent YAP activation has also been reported
(Leung & Zernicka-Goetz, 2013; Feng et al, 2014; Taniguchi et al,
2015), one can argue that the pro-proliferative role of YAP in cervi-
cal cancer cells may be independent of the Hippo pathway.
However, our present studies clearly indicated that the Hippo path-
way is involved in the YAP regulation of cervical cancer cell growth.
First of all, the results obtained from the multidimensional cancer
genomic datasets clearly indicated that in the cervical cancer tissue,
the Hippo pathway is frequently disrupted, indicated by the frequent
deletion and mutation of the genes involved in the Hippo pathway
(Fig EV1A). As a consequence of the disrupted Hippo pathway,
YAP, TAZ, and TEADs are frequently up-regulated in cervical cancer
tissues. Secondly, both TGF-a and AREG dephosphorylate MOB1,
LATS1, and YAP in cervical cells (Figs 6 and 7), suggesting that the
Hippo pathway is actively involved in the EGFR pathway regulation
of cervical cancer progression. Finally, knockdown of LATS1/2, the
major suppressors of YAP, results in dephosphorylation of YAP in
ME180 cervical cancer cells, leading to the significant increase in
the cell proliferation and AREG secretion in both 2D and 3D culture
systems. These results provide compelling evidence that the Hippo
pathway is actively involved in the regulation of cervical cancer
initiation and progression.
The causal relationship between high-risk HPV infection and
cervical cancer has been proposed because high-risk HPVs, such as
HPV16, HPV18, and HPV31, have been detected in up to 99.7% of
cervical squamous cell carcinomas and 94–100% of cervical adeno-
and adenosquamous carcinomas (Walboomers et al, 1999; Castell-
sague et al, 2006). Two types of high-risk HPVs, HPV16 and HPV18,
have been proposed to be responsible for more than 70% of all
cervical cancer cases (Schiffman et al, 2007). It is believed that the
high-risk HPV oncoproteins, E6 and E7, contribute to cervical
carcinogenesis by inactivating the cellular tumor suppressor
proteins p53 and pRb, respectively (Dyson et al, 1989; Scheffner
et al, 1990; Boyer et al, 1996). However, recent studies showed that
although persistent infection with high-risk HPV is a necessary step
for the development of cervical cancer, HPV alone is not sufficient
to initiate and drive the progression of cervical cancer (Melnikow
et al, 1998; Reshmi & Pillai, 2008). Moreover, evidence shows that
HPV E6-induced degradation of P53 may have no role on cell trans-
formation. For example, it has been shown that mutants of E6,
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Figure 10. HPV E6 stabilizes YAP protein.
A Effect of YAP mRNA levels in HT3 cells treated with or without E6 (400 nM)
for 60 min in McCoy’s 5A with 1% serum. Data were normalized with 18S
mRNA. Bars with same letters are not significantly different from each
other (P > 0.05). n = 4, P = 0.9407.
B YAP mRNA levels in HT3 cells treated with or without E6 (400 nM) for 48 h
in McCoy’s 5A with 1% serum. mRNA levels were measured with real-time
PCR. Data were normalized with 18S mRNA. Each bar represents
mean  SEM (n = 5). Bars with same letters are not significantly different
from each other (P > 0.05) (P = 0.3233).
C Western blot results showing YAP and EGFR protein levels after treatment
with MG132 or cycloheximide (CHX) for 4 h or 8 h. b-actin was used as a
protein loading control. Confluent HT3 cells were starved for 4 h before
treatment with MG132 (10 lM) or CHX (20 lg/ml) for 0, 4 or 8 h.
D HPV16 E6 protein prevented YAP protein from degradation. Confluent HT3
cells were starved for 4 h before treatment with or without CHX (20 lg/
ml), HPV16 E6, or CHX combined with HPV16 E6 for 8 h. Treatment of
starved HT3 cells with HPV16 E6 (400 nM) for 8 h suppressed degradation
of YAP, but not EGFR protein.
E Quantitative data showing relative YAP protein levels in (D). Protein levels
were normalized with b-actin and presented as ratios relative to that of
control. Each bar represents mean  SEM (n = 4). Bars with different
letters are significantly different from each other (Ctrl vs. CHX, P = 0.0003;
Ctrl vs. CHX+E6, P = 0.2665; Ctrl vs. E6, P = 0.0258).
F Western blot analysis showing that expression of HPV16 E6 in HT3 cells
increased the protein level of total YAP and casein kinase Ie, but decreased
the protein level of SOCS6. Importantly, HPV16 E6 increased YAP
phosphorylation at serine 127, but suppressed its phosphorylation at serine
397. HPV16 E6 had no effect on the level of b-TrcP, LATS1/2 and MOB1 in
HT3 cervical cancer cells.
G Western blot results showing that knockdown of endogenous E6 in HeLa
cells with HPV18 E6 siRNA (siE6) reduced YAP protein levels, but increased
SOCS6 protein levels.
H Western blot analysis showing that knockdown of SOCS6 in HT3 cells with
SOCS6 siRNA (siSOCS#1 and siSOCS6#2) increased total YAP protein,
enhanced phosphorylation of YAP protein at serine 127, but suppressed
phosphorylation of YAP at serine 397.
Data information: Quantitative data in (A) and (B) were analyzed for
significance using unpaired t-test in GraphPad Prism 5 with Welch’s
correction. Data in (E) were analyzed for significance using one-way ANOVA in
GraphPad Prism 5 with Tukey’s post hoc tests.
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Figure 11. YAP expression in normal, HPV16 E6, and HPV16 E6/E7-induced cancerous cervical tissues in a transgenic mouse model, and HPV16-containing
human foreskin keratinocyte raft cultures.
A–F Representative images showing expression of YAP (in red) in wild-type mouse cervical tissues (n = 5) (A), HPV16 E6-induced (C) and HPV16 E6/E7-induced (E)
mouse cervical tumor tissue (n = 4 each). Scale bars for (A), (C), and (E): 100 lm. High-resolution images showing the expression and cellular location of YAP in
normal cervical tissues (B), HPV16 E6-induced (D) and HPV16 E6/E7-induced (F) mouse cervical tumor tissue. Scale bars for (B), (D), and (F): 25 lm.
G, H Representative images showing expression of YAP (in red) in normal (G) and HPV16-containing human foreskin keratinocyte raft cultures (n = 5 each) (H). Scale
bars: 100 lm.
I, J High-resolution images showing the expression and cellular location of YAP in normal (I) and HPV16-containing human foreskin keratinocytes raft cultures (J).
Scale bars: 20 lm.
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defective in their ability to induce the degradation of p53, can
still immortalize human embryonic cells (Ishiwatari et al, 1994;
Nakagawa et al, 1995). E6 proteins from HPV-5 and HPV-8 do not
interact with P53 protein, but they are necessary for immortalization
of rodent fibroblasts (Elbel et al, 1997). On the contrary, E6 protein
of the low-risk HPV-1 inhibits P53 transactivation (Kiyono et al,
1994). Therefore, the exact molecular mechanism for HPV to drive
the initiation and progression of cervical cancer is not clear. Other
functions of E6 must also be involved in this process.
In the present study, for the first time, we show that the dysregu-
lation of the Hippo pathway may be involved in the HPV-induced
initiation and progression of cervical cancer. We found that HPV E6
protein is able to increase the level of YAP, the major effector of the
Hippo pathway, in cervical cancer cells by preventing YAP from
proteasome-dependent degradation. Regulation of protein turnover
by ubiquitin-mediated protein degradation has long been recognized
as an important mechanism for regulating the activity of signal
transduction pathways in cancer (Marmor & Yarden, 2004; Fulda
et al, 2012). Recent studies suggested YAP is inactivated by two
mechanisms: (i) the Ser127 phosphorylation-mediated spatial regu-
lation (nuclear–cytoplasmic shuttling); and (ii) the Ser397 (Ser381
in YAP protein isoform 2) phosphorylation-mediated temporal regu-
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Figure 12. Schematic cartoons showing the proposed mechanism underlying the Hippo signaling pathway regulation of cervical cancer progression.
A Schematic cartoons showing the proposed positive feedback loop in cervical cancer cells. Data in this study support the existence of an autocrine loop involving
EGF-like ligands/EGFR pathway/Hippo pathway/EGF-like ligands in regulating the proliferation and motility of cervical cancer cells, which plays a critical role in
cancer progression. Under normal conditions, low levels of EGF-like ligands such as TGF-a and AREG are not sufficient to activate EGFR. The inactive EGFR ensures
the activation of Hippo signaling pathway, which in turn results in ubiquitination-dependent degradation of YAP protein. In cervical cancer tissues, especially the
advanced-stage cancer tissues, the elevated nuclear YAP protein stimulates the expressions of TGF-a and AREG, which in turn activates the EGFR, leading to
suppression of LATS1 and MOB1 phosphorylation. Dephosphorylation of LATS1 and MOB1 results in the dissociation of LATS1/2-MOB1 complex, leading to inactivation
of the Hippo pathway and subsequent activation of the growth-promoting co-activator YAP. Activated YAP induces expression of growth factors such as TGF-a and
AREG to drive cervical cancer growth. YAP-induced growth factors such as TGF-a and AREG complete the autocrine loop by activating EGFR and YAP to drive the
proliferation of cancer cell and the production of growth-promoting factors in cervical cancer cells. HPV E6 protein maintains YAP protein level in the HPV-infected
normal and cancerous cervical cells by preventing YAP from proteasome-dependent protein degradation.
B Schematic cartoons showing the clinical relevance of the proposed positive feedback loop in cervical cancer. Multidimensional cancer genomics data analysis
indicates that very high frequency of alterations has been observed in genes involved in the Hippo/YAP/EGFR positive feedback loop in cervical cancer (we
acknowledge The Cancer Genome Atlas (TCGA) Data Portal for the datasets and the cBioPortal for Cancer Genomics for the online analysis tools).
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lation (the phosphodegron-induced degradation). These two mecha-
nisms function coordinately to suppress YAP oncogenic activity
(Zhao et al, 2010; Mo et al, 2014). The CK1d/ɛ and SOCS6 proteins
have been reported to be critical for YAP degradation (Zhao et al,
2010; Hong et al, 2014). However, expression of HPV E6 in HT3
cells induced a great increase in CK1d/ɛ and a drastic decrease in
p-YAP (S397), suggesting that CK1d/ɛ pathway may not contribute to
the HPV E6-mediated YAP protein turnover. However, expression of
HPV16 E6 in HT3 cells reduced SOCS6 protein levels, but increased
YAP protein levels, suggesting that SOCS6 may be involved in HPV
E6-mediated YAP protein stabilization in cervical cancer cells.
Interestingly, one recent report showed that the small t antigen
of polyomavirus (PyST) stabilizes YAP through promoting its
dephosphorylation (Hwang et al, 2014), suggesting that different
viruses may stabilize YAP protein in different ways. More experi-
ments are required to uncover the molecular mechanisms underly-
ing HPV oncoprotein stabilizing YAP protein. Importantly, the
interactions between the Hippo pathway and other high-risk HPV
oncoproteins (such as E5 and E7) may also play an important patho-
logical role in cervical carcinogenesis.
Finally, our data also show that HPV E6 not only increased YAP
protein levels, but also increased the expression of AREG mRNA
and the secretion AREG protein in culture medium. These observa-
tions suggest that HPV E6 protein may contribute to the Hippo-ERBB
positive signaling loop to drive the transformation and progression
of cervical cancer. Interestingly, previous studies have shown that
HPV16 E6 and E7 can transcriptionally activate EGFR expression
(Sizemore et al, 1998; Akerman et al, 2001). The HPV16 E6 causes
prolonged receptor protein tyrosine kinase signaling and enhances
internalization of phosphorylated receptor species (Spangle &
Munger, 2013). Internalized receptors maintain signaling potential
since they are phosphorylated at residues that promote receptor
association with signaling adaptor proteins and cause activation of
downstream signaling cascades (Sigismund et al, 2008; Goh et al,
2010). Collectively, these findings suggest that the Hippo-ERBB posi-
tive signaling loop may play an important role in mediating HPV
action during the initiation and progression of cervical cancer.
In summary, our study demonstrates that YAP is overexpressed
in human cervical cancer tissues and its expression is correlated
with cervical cancer progression. In vitro and in vivo findings
support the idea that the Hippo/YAP signaling pathway plays a criti-
cal role in the progression of cervical cancer. We also found that the
Hippo pathway interacts with the ERBB signaling pathway to form a
positive feedback signaling loop to regulate cervical cancer progres-
sion (Fig 12). Most importantly, HPV16 E6, via preventing protea-
some-dependent degradation of YAP, maintains the level of YAP
protein in the cervical cancer cells, which may serve to drive cancer
cell growth. Therefore, YAP might be a promising prognostic
biomarker for cervical cancer and a novel target for the develop-
ment of drugs against cervical cancer.
Materials and Methods
Chemicals
Transforming growth factor alpha (TGF-a), EGF, amphiregulin
(AREG), HPV16 E6, and ELISA kit of AREG were from R&D
systems Inc. (Minneapolis, MN). McCoy’s 5a and other cell
culture media were from Invitrogen (Carlsbad, CA). Fetal bovine
serum (FBS) was from Atlanta Biologicals, Inc. (Lawrenceville,
GA). The Ribogreen RNA Quantification Kit and Alexa-conjugated
secondary antibodies were from Life Technologies Corp. (Grand
Island, NY); RNeasy Mini Kit was from QIAGEN Inc. (Valencia,
CA). YAP siRNA, EGFR siRNA, LATS1 siRNA, LATS2 siRNA,
SOCS6 siRNA#1, and HPV18 E6 siRNA were from Dharmacon/
Thermo Scientific (Pittsburgh, PA). Lentiviral-based shYAP#1,
shYAP#2, and shLATS1/2 vectors were from Addgene (Cam-
bridge, MA). Lentivirus containing HPV16 E6 gene was from
Applied Biological Materials (ABM) Inc. (Richmond, BC, Canada).
PCR chemicals were from Invitrogen (Carlsbad, CA), QIAGEN
(Carlsbad, CA), or Bio-Rad (Hercules, CA). Antibodies against
YAP, phospho-YAP (Ser127), phospho-YAP (Ser397) LATS1,
phospho-LATS1, MOB1, phospho-MOB1, EGFR, phospho-EGFR,
ERK1/2, phospho-ERK-1/2, AKT, phospho-AKT, and b-TrcP were
from Cell Signaling Technology Inc. (Danvers, MA); siRNA of
SOCS6 and antibodies against SOCS6 and CKIe were from Santa
Cruz (Dallas, Texas). Antibodies against b-actin were from
Sigma-Aldrich (St. Louis, MO). Peroxidase-conjugated secondary
antibodies for Western blot analysis were from Jackson
ImmunoResearch Laboratories Inc. (West Grove, PA); the
SuperSignal West Femto Chemiluminescent Substrate Kit was
from Pierce/Thermo Scientific (Rockford, IL); Optitran nitrocellu-
lar transfer membrane was from Schleicher & Schuell Bioscience
(Dassel, Germany); MG132, cycloheximide, AG1478, LY294002,
U0126, and SB203580 were from EMD Millipore Corporation
(Billerica, MA). All other molecular-grade chemicals were
purchased from Sigma (St. Louis, MO), Fisher (Pittsburgh, PA),
or United States Biochemical (Cleveland, OH).
Cell lines and human cervical tissue array
ME180, HT3, Ect1/E6E7, HeLa, and End1/E6E7 cells were
purchased from ATCC (Manassas, VA). ME180 cells were derived
from an omental metastasis of a recurrent cervical epidermoid carci-
noma (Sykes et al, 1970). HT3 cells were derived from tumor cells
of a cervical papilloma patient that recurred from the cervix and
lymph nodes (Fogh et al, 1977). Ect1 and End1/E6E7 cell lines
were established from normal epithelial tissue taken from a
premenopausal woman undergoing hysterectomy for endometriosis
(Fichorova et al, 1997; Fichorova & Anderson, 1999). Cells used in
these experiments were from passages 6–12. All cell lines were
validated by short tandem repeat (STR) polymorphism analysis
performed by the Genetica DNA Laboratories (Burlington, NC,
USA). The cervical carcinoma and normal tissue arrays, with stage
and grade information, were purchased from US Biomax (Rockville,
MD). This array contained 25 early-stage cases, 45 advanced-stage
cases, and 10 normal tissues.
Detection of YAP expression in human cervical cancer and
normal tissues by immunohistochemistry
YAP protein expression in human cervical tissues was detected
by using peroxidase-based immunohistochemistry as described
previously (Fu et al, 2014). Briefly, human tissues were deparaf-
finized with xylene, rehydrated with graded ethanol series, and
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then autoclaved in an unmasking solution (Vector Laboratories,
Burlingame, CA) for antigen retrieval before blocking endogenous
peroxidase activity with 3% hydrogen peroxide. Tissues were
next blocked with 10% normal donkey serum (NDS) at room
temperature for 1 h followed by incubation with primary antibod-
ies at 4°C for 16 h. Biotinylated secondary antibody and strepta-
vidin peroxidase complex (DAKO LSAB Kit, Carpinteria, USA)
were added consecutively for ten minutes at room temperature.
The immunosignal was visualized with DAB kit (Invitrogen,
Carlsbad, CA). The sections were counterstained with Mayer’s
hematoxylin. For negative controls, the primary antibody was
replaced with blocking buffer containing the same amount of IgG
from the non-immune rabbit serum. Sections were scanned with
an iSCAN Coreo Slide Scanner (Ventana Medical Systems, Inc.
Oro Valley, AZ). The intensity of the positive immunosignal was
quantified using Aperio ImageScope software (Vista, CA). The
intensity of positive signal and the positivity (i.e., the ratio of
positive cell number relative to the total cell) of each section
were recorded.
Western blot analysis
Western blot was used to determine protein levels as described
previously (Wang et al, 2013). Briefly, normal or treated cells
were harvested on ice with ice-cold lysis buffer containing 10 mM
Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
NaF, 20 mM Na4P2O7, 1% Triton X-100, 10% glycerol, 0.1% SDS
and 0.5% deoxycholate, and protease and phosphatase inhibitor
cocktails. Samples (30 lg protein) were loaded to a 10% SDS–
PAGE gel, fractioned through electrophoresis, and transferred onto
nitrocellulose membranes. The membranes were blocked with 5%
BSA and then probed with appropriate primary and horseradish
peroxidase (HRP)-conjugated secondary antibodies. The
immunosignal was detected using a Thermo Scientific SuperSignal
West Femto Chemiluminescent Substrate Kit. The images were
captured and analyzed using a UVP gel documentation system
(UVP, Upland, CA).
Quantitative real-time PCR
Quantitative real-time PCR (qRT–PCR) was used to determine mRNA
expression. Total RNA was prepared with TRIzol reagent (Invitro-
gen, Carlsbad, CA) and QIAGEN RNeasy mini kit (QIAGEN,
Carlsbad, CA). RNA concentration was determined with Ribogreen
RNA quantification kit. Reverse transcription was done by using high-
capacity cDNA reverse transcription kit (Applied Biosystems, Grand
Island, NY). PCR was performed in a Bio-Rad CFX96 real-time fast
PCR system. The following primers were used for AREG: forward:
50-CGAACCACAAATACCTGGCTA-30; reverse: 50-TCCATTTTTGCCT
CCCTTTT-30. The following primers were used for 18S (used as a
loading control): forward: 50-GGCGTCC CCCAACTTCTTA-30; reverse:
50-GGGCATCACAGACCTGTTATT-3. All samples were amplified in
triplicate.
Establishment of YAP-overexpressing and knockdown cell lines
Nine cell lines expressing different levels of YAP protein were
established to determine the role of YAP in cervical cancer cell
proliferation. Briefly, ME180, HT3, and Ect1/E6E7 cells were
cultured to 40% confluent and then transfected with retrovirus-
based YAP overexpression constructs. The efficiency of these
vectors has been reported previously (Dong et al, 2007). The
following nine stable cell lines were established: (i) ME180-MXIV,
HT3-MXIV, and Ect1-MXIV control cell lines were transfected with
the empty control vector MXIV and express endogenous YAP; (ii)
the ME180-YAP, HT3-YAP, and Ect1-YAP cell lines were trans-
fected with a vector overexpressing wild-type YAP protein; and
(iii) the ME180-YAPS127A, HT3-YAPS127A, and Ect1-YAPS127A cell
lines expressing a constitutively activated YAP mutant. Notably,
mutation of YAP protein (serine to alanine at residue 127)
prevents YAP phosphorylation, leading to its nuclear localization
and constitutive activation. Stable YAP- and YAPS127A-expressing
clones were selected using G418. YAP expression was confirmed
by Western blot and RT–PCR analysis. The effect of YAP on cervi-
cal cancer cell proliferation was also determined by knockdown
of YAP protein using the RNA interference technique. Briefly,
60% confluent ME180 cells were transfected with siNeg (a cy5-
labeled non-target siRNA as control) or YAP siRNAs for 6 h using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Flowing the previ-
ous report (Rosenbluh et al, 2012), lentiviral-based shYAP#1 and
shYAP#2 were used to establish two cell lines with YAP knock-
down. Successful knockdown of YAP was also confirmed by RT–
PCR and Western blot.
Cell proliferation, cell migration, and colony formation assays
Cell proliferation was determined by counting cell number with an
Invitrogen Countess automated cell counter (Carlsbad, CA) and
detecting cell cycle progression with flow cytometry. Cell migration
was determined using wound-healing assay with a protocol estab-
lished in our laboratory (Wang et al, 2012a). The ability of anchor-
age-free cell growth was assessed with soft agar cell colony
formation assay using CytoSelect 96-Well Cell Transformation Assay
kit (Cell Biolabs, Inc.).
In vivo tumorigenicity
Animal handling and all experimental procedures were approved by
the Institutional Animal Care and Use Committee (IACUC) of the
University of Nebraska Medical Center. ME180-YAP and ME180-
YAPS127A cells (6 × 106 cells suspended in 0.1 ml PBS) were injected
subcutaneously into the left dorsal flank of 6-week-old female
athymic nude mice. ME180-MXIV cells with control vectors were
injected into right dorsal flank of these mice. The tumor diameter
was measured and documented every 4 days. The tumor volume
(mm3) was estimated by measuring the longest and shortest diame-
ter of the tumor and calculating as follows: volume = (shortest
diameter)2 × (longest diameter) × 3.14/6. All mice were euthanized
4 weeks after tumor cell inoculation. Tumors were collected,
weighed, and processed for preparation of frozen sections, protein
and RNA. Ki67 expression in the tumor xenografts was used as a
cell proliferation index and was examined using fluorescent
immunohistochemistry with a protocol described previously (Fu
et al, 2014). Similarly, ME180-CTRL and ME180-shYAP#1 cells
(5 × 106 cells suspended in 0.1 ml PBS) were injected subcuta-
neously into the left or right dorsal flank of 6-week-old female
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athymic nude mice, and all mice were euthanized 1 month after
tumor cell inoculation.
Examination of the expression of YAP in K14E6/E7 transgenic
mice and HPV16-contained organotypic “3D raft” cultures
Control (wild-type), HPV16 E6, and HPV16 E6/E7 cervical cancer
mouse model has been reported previously (Brake & Lambert, 2005;
Shai et al, 2007). Briefly, the keratin-14 (K14) promoter was used to
direct E6 or E6/E7 expression in mice. All control K14E6 and
K14E6/E7 transgenic mice were treated with estrogen for 6 months.
Cervical cancer was observed in KE6 and K14E6/E7 mice (Brake &
Lambert, 2005; Shai et al, 2007). Normal and cancerous cervical
tissues from control and estrogen-induced K14E6 and K14E6/E7 mice
were harvested and processed for preparation of paraffin section with
the protocol described previously (Brake & Lambert, 2005).
Organotypic cultures were generated as previously described
(Lambert et al, 2005; Zehbe et al, 2009). Briefly, the immortalized
keratinocyte cells (NIKS) were transfected with or without HPV16
DNA, after selection with G418 (Invitrogen) for 4 days, the cells
were cultured in fresh complete F medium for additional 3 or
4 days. Following the guiding line to prepare dermal equivalent
(rafts) and plate Keratinocytes onto the rafts, each raft culture was
initiated for 2 × 105 NIKS cells and then cultured this organotypic
“raft” for another 16 days. The cultures were fixed in 10% buffered
formalin and embedded in paraffin. The expression and localization
of YAP protein in organotypic cultures and normal and cancerous
mouse cervical tissues were determined by using alkaline phos-
phatase-based VECTASTAIN ABC-AP kit (Cat. No. AK-5000).
Vector Red Substrate kit (Cat. No. AK-5100) (Vector Laboratories,
Burlingame, CA) was used to visualize immunosignal of YAP
protein. Sections were scanned with an iSCAN Coreo Slide Scanner
(Ventana Medical Systems, Inc. Oro Valley, AZ).
Human cervical cancer genomic data analysis
Genomic data mining was performed using cBioPortal for Cancer
Genomics (available at http://www.cbioportal.org) as described
previously (Gao et al, 2013). For the analysis of YAP alterations in
different cancer types, we selected all 90 available studies. For other
analysis associated with cervical cancer, we used cervical cancer
(CESC) dataset from The Cancer Genome Atlas (TCGA) Data Portal
in accordance with the publication guidelines (TCGA, Provisional).
YAP mRNA expression values are converted to z-scores to facilitate
comparison and definition of alteration thresholds, and mRNA
expression beyond z-score threshold  2 would be considered up-
or down-regulation (Gao et al, 2013). Correlation analysis and
network analysis were carried out following a recently described
cBioPortal protocol (Gao et al, 2013).
Statistical analysis
All experiments were repeated at least four times unless otherwise
noted. Data are presented as mean  SEM. Statistical analysis was
conducted using GraphPad Prism software (GraphPad Software, Inc.
La Jolla, CA). Data were analyzed for significance using one-way
ANOVA with Tukey’s post hoc tests. A value of P < 0.05 was consid-
ered statistically significant.
Expanded View for this article is available online:
http://emmm.embopress.org
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The paper explained
Problem
Globally, cervical cancer claims the lives of more than 250,000 women
each year. Although HPV has been identified as a causative reagent
for cervical cancer, recent studies indicate that HPV alone is not suffi-
cient for malignant transformation of the cervical epithelium. The
exact molecular mechanisms underlying cervical cancer initiation and
progression are largely unknown.
Results
We found that the Hippo/YAP pathway, via interacting with ERBB
signaling pathways, forms an autocrine loop to drive the initiation
and progression of cervical cancer. HPV E6 contributes to this carcino-
genic feed-forward loop by stabilizing YAP oncoproteins. The clinical
relevance of our findings is supported by results from TCGA multidi-
mensional cancer genomics data and an accepted transgenic mouse
model of cervical cancer.
Impact
The present study describes a previously unprecedented mechanism
underlying cervical cancer development and progression. Our study
provides a new insight into our understanding on the etiology of
cervical cancer and suggests that combined targeting of the Hippo
and ERBB signaling pathways may provide a new therapeutic strategy
for prevention and treatment of cervical cancer.
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For more information
Read more on cervical cancer:
http://www.cancer.org/cancer/cervicalcancer/
http://www.cancer.gov/types/cervical
Read more on the Hippo pathway and gynecological cancers:
http://www.unmc.edu/obgyn/research/ocl/index.html
http://www.nature.com/nrc/journal/v13/n4/full/nrc3458.html
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